What type of prescription drug does Seladelpar belong to?

Seladelpar (Seladelpar) is an innovative targeted drug for primary biliary cholangitis (PBC) . It is administered in the form of oral capsules and is mainly used to treat adult PBC patients, especially those who have insufficient response or intolerance to ursodeoxycholic acid (UDCA). Data show that Siladepa belongs to PPARδ (peroxisome proliferator-activated receptor δ) agonist drugs. It improves bile excretion dysfunction and reduces bile duct epithelial inflammation by activating specific signaling pathways in the liver, thereby achieving the purpose of alleviating cholestasis.

In the treatment landscape of chronic cholestatic diseases, traditional methods mainly rely on UDCA and thiabecholic acid, and the emergence of siladepa is considered to fill the key gap in the treatment of PBC. Different from traditional methods of improving bile flow, Siladepa achieves systemic improvement by regulating gene expression, reducing the production of inflammatory mediators, and increasing the activity of bile-dependent transporters. Therefore, it is regarded as a new generation of more targeted PBC treatment options.

In terms of usage, the drug is taken orally once a day and is suitable for long-term maintenance treatment. It requires high regularity in life, but it is easy to take. For patients who have poor response to UDCA, the combined use of Siladepa and UDCA can enhance the overall efficacy; for patients who cannot tolerate UDCA (such as worsening itching or severe gastrointestinal discomfort), Siladepa can be used alone and still achieve significant improvements in biochemical indicators.

SincePBC is more common in middle-aged women and develops slowly but can gradually cause liver fibrosis. Therefore, it is particularly critical to choose drugs with good safety and long-term use. Overseas safety data suggest that Siladepa is well tolerated in long-term management, and common adverse reactions are mostly mild to moderate and manageable.

Reference materials:https://go.drugbank.com/drugs/DB12390